文献速递乳腺癌

表观遗传开关介导的病毒模拟逃逸导致乳腺癌化疗耐药

Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.
PubMed 文献 · Cancer Discov · 2020-06-16

该研究探讨紫杉烷耐药三阴性乳腺癌(TNBC)中病毒模拟反应的逃逸机制。研究发现,适应紫杉烷代谢应激的表观遗传状态使DNA低甲基化区域被H3K27me3大染色质结构域覆盖,从而抑制转座元件(TE)表达并逃逸病毒模拟反应。抑制EZH2可解除TE抑制,通过病毒模拟反应产生双链RNA并抑制肿瘤生长,揭示表观遗传治疗脆弱性。

要点

  • 紫杉烷耐药TNBC通过H3K27me3大染色质结构域抑制TE表达,逃逸病毒模拟反应。
  • EZH2抑制剂可解除TE抑制,诱导双链RNA产生并抑制耐药TNBC生长。
  • 该表观遗传状态定义了紫杉烷耐药TNBC对EZH2抑制剂的治疗脆弱性。

核心结论

  • 紫杉烷耐药TNBC通过表观遗传状态逃逸病毒模拟反应得以生长,该状态对EZH2抑制剂治疗形成脆弱性。

研究设计与样本

  • 原文未报告具体研究设计与样本量,仅涉及紫杉烷耐药三阴性乳腺癌(TNBC)的机制研究。

主要发现

  • 紫杉烷耐药TNBC中,DNA低甲基化且富含转座元件(TE)的位点被H3K27me3大染色质结构域覆盖,维持TE抑制。
  • EZH2抑制剂可解除紫杉烷耐药TNBC中的TE抑制,导致双链RNA产生并通过病毒模拟反应抑制生长。

临床怎么用

  • EZH2抑制剂可能作为紫杉烷耐药TNBC的候选表观遗传治疗策略。

局限性

  • 原文未报告临床样本量、疗效数据及安全性信息,结论主要基于机制性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant triple-negative breast cancer (TNBC). This is enabled by an epigenetic state adapted to taxane-induced metabolic stress, where DNA hypomethylation over loci enriched in transposable elements (TE) is compensated by large chromatin domains of H3K27me3 to warrant TE repression. This epigenetic state creates a vulnerability to epigenetic therapy against EZH2, the H3K27me3 methyltransferase, which alleviates TE repression in taxane-resistant TNBC, leading to double-stranded RNA production and growth inhibition through viral mimicry response. Collectively, our results illustrate how epigenetic states over TEs promote cancer progression under treatment and can inform about vulnerabilities to epigenetic therapy. SIGNIFICANCE: Drug-resistant cancer cells represent a major barrier to remission for patients with cancer. Here we show that drug-induced metabolic perturbation and epigenetic states enable evasion from the viral mimicry response induced by chemotherapy in TNBC. These epigenetic states define a vulnerability to epigenetic therapy using EZH2 inhibitors in taxane-resistant TNBC.See related commentary by Janin and Esteller, p. 1258.This article is highlighted in the In This Issue feature, p. 1241.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Deblois G, Tonekaboni SAM, Grillo G, et al. Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. Cancer Discov. 2020. PMID: 32546577. doi:10.1158/2159-8290.CD-19-1493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。